Lung Cancer Liquid Biopsy Global Market Opportunities And Strategies To 2035

Lung Cancer Liquid Biopsy Market Definition

Lung cancer liquid biopsy refers to a minimally invasive diagnostic approach used to detect and monitor lung cancer by analyzing tumor-derived materials, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and other biomarkers, in bodily fluids, primarily blood. This market encompasses the revenues generated by entities, including biotechnology companies, diagnostic laboratories and healthcare institutions, that develop and provide liquid biopsy-based products and services for lung cancer diagnosis and management. These tests are used by oncologists, pathologists and healthcare providers for patients suspected of having lung cancer, as well as those undergoing treatment or post-treatment surveillance. The lung cancer liquid biopsy market consists of sales by entities (organizations, sole traders and partnerships) that provide products and services for the detection and management of lung cancer using liquid biopsy. This includes instruments, consumables, kits and reagents, as well as software and related services. These solutions support various stages such as sample collection and processing, assay development and testing, data analysis and interpretation and clinical decision support and are based on technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR).

Lung Cancer Liquid Biopsy Market Segmentation

The lung cancer liquid biopsy market is segmented by product, by technology, by biomarker, by clinical application and by end user.

By Product –
The lung cancer liquid biopsy market is segmented by product into:

• a) Instruments
• b) Consumables, Kits And Reagents
• c) Software And Services

The instruments market was the largest segment of the lung cancer liquid biopsy market segmented by product, accounting for 48.8% or $545.7 million of the total in 2025. Going forward, the software and services segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by product, at a CAGR of 27.9% during 2025-2030.

By Technology –
The lung cancer liquid biopsy market is segmented by technology into:

• a) Multi-Gene-Parallel Analysis (NGS)
• b) Single-Gene Analysis (PCR Microarrays)

The single-gene analysis (PCR microarrays) market was the largest segment of the lung cancer liquid biopsy market segmented by technology, accounting for 51.7% or $577.4 million of the total in 2025. Going forward, the multi-gene-parallel analysis (NGS) segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by technology, at a CAGR of 27.5% during 2025-2030.

By Biomaker –
The lung cancer liquid biopsy market is segmented by biomaker into:

• a) Circulating Tumor Deoxyribonucleic Acid
• b) Extracellular Vesicles
• c) Circulating Tumor Cells
• d) Other Biomarkers

The circulating tumor deoxyribonucleic acid market was the largest segment of the lung cancer liquid biopsy market segmented by biomarker, accounting for 100.0% or $1,117.8 million of the total in 2025. Going forward, the circulating tumor deoxyribonucleic acid segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by biomarker, at a CAGR of 19.9% during 2025-2030.

By Clinical Application –
The lung cancer liquid biopsy market is segmented by clinical application into:

1. a) Therapy Selection
2. b) Treatment Monitoring
3. c) Early Cancer Screening
4. d) Recurrence Monitoring
5. e) Other Applications

The therapy selection market was the largest segment of the lung cancer liquid biopsy market segmented by clinical application, accounting for 38.7% or $433.0 million of the total in 2025. Going forward, the therapy selection segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by clinical application, at a CAGR of 23.2% during 2025-2030.

By End User –
The lung cancer liquid biopsy market is segmented by end user into:

1. a) Diagnostics And Imaging Centers
2. b) Hospitals
3. c) Academics And Research Centers
4. d) Other End Users

The hospitals market was the largest segment of the lung cancer liquid biopsy market segmented by end user, accounting for 38.9% or $435.3 million of the total in 2025. Going forward, the academics and research centers segment is expected to be the fastest-growing segment in the lung cancer liquid biopsy market segmented by end user, at a CAGR of 25.5% during 2025-2030.

By Geography - The lung cancer liquid biopsy market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• Taiwan
• South Korea
o South East Asia
• Indonesia
o North America
• USA
• Canada
o South America
• Brazil
o Western Europe
• France
• Germany
• UK
• Italy
• Spain
o Eastern Europe
• Russia
o Middle East
o Africa

North America was the largest region in the lung cancer liquid biopsy market, accounting for 68.0% or $759.9 million of the total in 2025. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the lung cancer liquid biopsy market will be Africa and Middle East where growth will be at CAGRs of 45.9% and 40.1% respectively. These will be followed by Western Europe and Asia-Pacific where the markets are expected to grow at CAGRs of 30.2% and 28.5% respectively.

Lung Cancer Liquid Biopsy Market Drivers

The key drivers of the lung cancer liquid biopsy market include: Rising Demand For Non-Invasive And Repeatable Cancer Testing During the forecast period, the rising demand for non-invasive and repeatable cancer testing is expected to propel the growth of the lung cancer liquid biopsy market. Traditional tissue biopsies are often invasive, costly and difficult to perform multiple times, limiting their suitability for continuous monitoring. In contrast, liquid biopsy uses simple blood samples, enabling safer and more convenient testing. This allows clinicians to track disease progression, detect mutations and assess treatment response in real time. As healthcare providers prioritize patient comfort and early detection, the adoption of such minimally invasive diagnostic solutions is rising, thereby supporting market expansion and improving overall cancer management outcomes. The rising demand for non-invasive and repeatable cancer testing growth contribution during the forecast period in 2026 is 2.0%.

Lung Cancer Liquid Biopsy Market Restraints

The key restraints on the lung cancer liquid biopsy market include: Limited Sensitivity In Early-Stage Lung Cancer Detection During the forecast period, limited sensitivity in early-stage lung cancer detection is expected to hinder the growth of the lung cancer liquid biopsy market. In early-stage disease, tumor-derived biomarkers such as circulating tumor DNA are present at very low concentrations, reducing test accuracy and increasing the risk of false-negative results. This limits clinical confidence and delays widespread adoption in screening programs. As a result, healthcare providers may continue to rely on conventional imaging and tissue biopsy methods for early diagnosis. The inability to consistently detect cancer at an early stage weakens the value proposition of liquid biopsy solutions, thereby slowing market penetration and revenue growth despite ongoing technological advancements. Growth affected by the limited sensitivity in early-stage lung cancer detection during the forecast period in 2026 is -2.5%.

Lung Cancer Liquid Biopsy Market Competitive Landscape

Major Competitors are:

F. Hoffmann-La Roche Ltd

QIAGEN NV

Guardant Health Inc

Thermo Fisher Scientific Inc

Eurofins Scientific SE

Other Competitors Include:

NeoGenomics Laboratories Inc

Agilent Technologies Inc

Sysmex Corporation

Illumina Inc

Biodesix Inc

Bio-Rad Laboratories

Menarini Silicon Biosystems

GRAIL

IMBdx

Lucence Diagnostics Pte Ltd

Amoy Diagnostics Co., Ltd

Burning Rock Biotech Ltd

Singlera Genomics

HaploX

Geneseeq Technology Inc

Berry Oncology Co., Ltd

Shenzhen Yucebio Technology Co., Ltd

Natera

Foundation Medicine

NYU Langone Health’s Perlmutter Cancer Center

Datar Cancer Genetics

Myriad Genetics Inc

LungLife AI Inc

Biodesix Inc

Tempus

OncoHelix

Exact Sciences

Menarini Silicon Biosystems Inc

Inivata Ltd

Sophia Genetics

Lung Cancer Liquid Biopsy Market Trends

Major trends shaping the lung cancer liquid biopsy market include: Advancing ctDNA-Guided Adaptive Immunotherapy For Real-Time Cancer Treatment Optimization Key players operating in the lung cancer liquid biopsy market are advancing circulating tumor DNA (ctDNA)-driven precision oncology solutions, enabling real-time treatment monitoring, adaptive immunotherapy strategies and improved patient stratification to enhance clinical outcomes and personalized cancer care. For instance, in December 2025, Cancer Research Institute, a US-based biotechnology company, has initiated the next phase of its BR.36 Phase 2/3 clinical trial, leveraging liquid biopsy technology from Labcorp Holdings Inc., a US-based healthcare company, to guide precision immunotherapy for advanced lung cancer. The study uses circulating tumor DNA (ctDNA) to monitor early responses to treatment and adapt therapy accordingly. Patients showing high risk of disease progression may receive a combination of immunotherapy and chemotherapy, improving personalized care strategies. Led by leading research institutions including Johns Hopkins Kimmel Cancer Center, the trial aims to enhance treatment outcomes and establish ctDNA as a key tool in real-time cancer management. Rising Focus on AI-Integrated Multi-Omics for Minimal Residual Disease Detection and Recurrence Monitoring Companies operating in the lung cancer liquid biopsy market are increasingly focusing on post-treatment monitoring and early detection of recurrence by leveraging multi-omics platforms and artificial intelligence. This strategic shift is driven by the need to address minimal residual disease (MRD), where conventional imaging often fails to detect microscopic disease progression. By integrating diverse biomarkers such as circulating tumor DNA (ctDNA) and RNA signatures with advanced predictive algorithms. For instance, Flomics Biotech, an Italy-based biotechnology company specializing in RNA-based liquid biopsy for early, multi-cancer detection, has joined the Eurostars funded project LUMINA, an international initiative aimed at advancing the early detection of lung cancer recurrence through liquid biopsy and artificial intelligence. The project focuses on identifying minimal residual disease (MRD) in lung cancer patients after curative intent treatment, a critical unmet need since a substantial proportion of these patients eventually relapse. Flomics contributes its total RNA analysis platform for liquid biopsy to capture complex circulating RNA signatures, which are combined with other multi omic biomarkers such as circulating tumor DNA and integrated into AI driven predictive models. This approach is designed to detect molecular evidence of recurrence earlier than conventional imaging or clinical methods, enabling timely intervention.

Opportunities And Recommendations In The Lung Cancer Liquid Biopsy Market

Opportunities – The top opportunities in the lung cancer liquid biopsy market segmented by product will arise in the consumables, kits and reagents segment, which will gain $933.4 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by technology will arise in the multi-gene-parallel analysis (NGS) segment, which will gain $1,278.8 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by biomarker will arise in the circulating tumor deoxyribonucleic acid segment, which will gain $1,647.7 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by clinical application will arise in the therapy selection segment, which will gain $795.0 million of global annual sales by 2030. The top opportunities in the lung cancer liquid biopsy market segmented by end user will arise in the hospitals segment, which will gain $723.9 million of global annual sales by 2030. The lung cancer liquid biopsy market size will gain the most in the USA at $941.4 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the lung cancer liquid biopsy companies to focus on ctDNA-guided precision oncology expansion, focus on AI-driven recurrence monitoring solutions, focus on AI-enabled early detection platforms, focus on software and services expansion, focus on multi-gene NGS-based liquid biopsy platforms, focus on extracellular vesicle-based liquid biopsy development, expand in emerging markets, continue to focus on developed markets, focus on value-based and tiered pricing strategies, focus on clinical education and scientific evidence promotion, focus on digital outreach and patient awareness campaigns, focus on early cancer screening applications and focus on academic and research center partnerships.